Hormone Therapy Use After Premature Surgical Menopause Based on Prescription Records: A Population-Based Study

Jang, Ji-Hyun; Arora, Nalini; Kwon, Janice S.; Hanley, Gillian E.

doi:10.1016/j.jogc.2020.03.022

Cited by 13 publications

(17 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…11 An analysis of women younger than age 50 years in British Columbia who underwent oophorectomy noted that 55% of women started ET. 12 In line with these data, we found that 62% of women initiated ET after oophorectomy. However, even among women who start ET the duration of use is often short.…”

Section: Discussionsupporting

confidence: 84%

Use of Estrogen Therapy After Surgical Menopause in Women Who Are Premenopausal

Suzuki

Huang

Melamed

et al. 2022

Obstetrics &Amp; Gynecology

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 84%

Use of Estrogen Therapy After Surgical Menopause in Women Who Are Premenopausal

Suzuki

Huang

Melamed

et al. 2022

Obstetrics &Amp; Gynecology

View full text Add to dashboard Cite

show abstract

“…In Canadian and US samples of women undergoing premature surgical menopause, approximately half received any hormonal medication, although the duration of therapy was short, often 1 year or less. 15,16 Initiation of hormonal medications was less frequent in our sample, though the relatively short duration may be similar given the low percentage of visits where hormone use was reported, suggesting even greater unmet need. Notably, participants in the Canadian study had higher income than participants in the WIHS, and participants in the US study were majority White compared to the WIHS's majority Black population.…”

Section: Discussionmentioning

confidence: 61%

“…To our knowledge, there are no prior studies of hormone use among all premature and early menopausal people in the US for comparison. In Canadian and US samples of women undergoing premature surgical menopause, approximately half received any hormonal medication, although the duration of therapy was short, often 1 year or less 15,16 . Initiation of hormonal medications was less frequent in our sample, though the relatively short duration may be similar given the low percentage of visits where hormone use was reported, suggesting even greater unmet need.…”

Section: Discussionmentioning

confidence: 70%

Premature and early menopause among US women with or at risk for HIV

et al. 2022

View full text Add to dashboard Cite

Objective: Little is known about the prevalence and treatment of premature and early menopause among people with HIV. We described premature and early menopause and subsequent hormonal treatment in a longitudinal cohort of women living with or at risk for HIV in the US.Methods: Data from the Women's Interagency HIV Study between 2008 and 2020 were analyzed to describe premature and early menopause among cohort participants under the age of 51.Results: Of 3,059 eligible women during the study period, 1% (n ¼ 35) underwent premature menopause before age 41, 3% (n ¼ 101) underwent menopause between ages 41 and 46, and 21% (n ¼ 442) underwent menopause between ages 46 and 50, inclusive. Of participants who experienced menopause before age 41, between age 41 and 45, and between ages 46 and 50, 51%, 24%, and 7% (respectively) received either menopausal hormone therapy or hormonal contraception.Conclusion: These findings suggest that disparities in receipt of recommended hormone therapy for premature and early menopause may contribute, in part, to evident health disparities, such as cardiovascular disease, osteoporosis, and overall mortality. They also suggest a substantial need for education among people experiencing early menopause and their providers, with the goal of improving access to hormone therapy based on guidelines to address health disparities and minimize future health consequences.

show abstract

“…Thus, the clinical guidelines are clear and most women with early or premature menopause should be using CHC or MHT. Previous studies, however, have found results indicating an insufficient use of MHT in women with POI (83) and premature menopause after bilateral oophorectomy (84,85).…”

Section: Mht and Early/premature Menopausementioning

confidence: 85%

Epidemiological and Clinical Aspects of Hormonal Contraception and Menopausal Hormone Therapy in Women

Sundell

2023

Linköping University Medical Dissertations

View full text Add to dashboard Cite

BackgroundThe main indication for therapy with female sex hormones in younger women is contraception, whereas women around and after menopause might use menopausal hormone therapy (MHT) to manage vasomotor symptoms. The use of hormonal contraception and MHT, both referred to as hormone therapy in this thesis, has changed over time and varies in different age groups and populations depending on indications, definitions of use, current knowledge, and clinical guidelines. The use of oestrogen may increase the risk of venous thromboembolism and therefore combined hormonal contraceptives (CHC) are not recommended to women with obesity. Women with early or premature menopause are recommended hormone therapy at least until the normal age of menopause to avoid the increased morbidity and mortality caused by oestrogen deficiency.

show abstract

Hormone Therapy Use After Premature Surgical Menopause Based on Prescription Records: A Population-Based Study

Cited by 13 publications

References 22 publications

Use of Estrogen Therapy After Surgical Menopause in Women Who Are Premenopausal

Use of Estrogen Therapy After Surgical Menopause in Women Who Are Premenopausal

Premature and early menopause among US women with or at risk for HIV

Epidemiological and Clinical Aspects of Hormonal Contraception and Menopausal Hormone Therapy in Women

Contact Info

Product

Resources

About